OXiGENE is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.

Thursday, February 4, 2010
OXiGENE Announces Results of Stockholder Vote on Proposed Merger With VaxGen

Monday, December 7, 2009
OXiGENE Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at ASH Conference